Since 1996, it has been postulated that TG2 plays a role in breast cancer [26], demonstrating its involvement in fostering the EMT [48], advancing metastatic progression [65,66,67], and contributing to drug resistance [36,37,38]; see Figure 6. Here, TGM2 is linked to breast carcinoma.